Stay updated on Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.

Latest updates to the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page
- Check5 days agoChange DetectedAdds sponsor/collaborator institutions—Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine—and a new 'Helpful Links Provided by' section.SummaryDifference0.6%

- Check12 days agoChange DetectedThe affiliations for Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, and for Washington University School of Medicine, have been removed. The 'Helpful Links Provided by' section is no longer displayed.SummaryDifference0.2%

- Check34 days agoChange Detected- Added a government-funding notice about potential delays and updated operating status guidance, and a major version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference3%

- Check41 days agoChange DetectedRemoved a specific resource entry for a disease and updated the page version to v3.1.0.SummaryDifference0.5%

- Check55 days agoChange DetectedRevision updated to v3.0.2 and Back to Top removed; no core content or critical information is affected.SummaryDifference0.2%

- Check62 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.2%

Stay in the know with updates to Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.